NCT00050440 2013-01-08Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial CarcinomaJohnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 2 Completed50 enrolled